Literature DB >> 16733845

Antibiotics and probiotics in treatment of inflammatory bowel disease.

Paolo Gionchetti1, Fernando Rizzello, Karen-M Lammers, Claudia Morselli, Lucia Sollazzi, Samuel Davies, Rosy Tambasco, Carlo Calabrese, Massimo Campieri.   

Abstract

Many experimental and clinical observations suggest that intestinal microflora plays a potential role in the pathogenesis of inflammatory bowel disease (IBD). Manipulation of the luminal content using antibiotics or probiotics represents a potentially effective therapeutic option. The available studies do not support the use of antibiotics in ulcerative colitis (UC). Antibiotics are effective in treating septic complications of Crohn's disease (CD) but their use as a primary therapy is more controversial, although this approach is frequently and successfully adopted in clinical practice. There is evidence that probiotic therapy may be effective in the prevention and treatment of mild to moderate UC. In contrast, a lack of successful study data at present precludes the widespread use of probiotics in the treatment of CD. Both antibiotics and probiotics appear to play a beneficial role in the treatment and prevention of pouchitis and further trials are warranted to fully quantify their clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16733845      PMCID: PMC4087861          DOI: 10.3748/wjg.v12.i21.3306

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  73 in total

1.  Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.

Authors:  R D Hurst; M Molinari; T P Chung; M Rubin; F Michelassi
Journal:  Arch Surg       Date:  1996-05

2.  Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

Authors:  P Gionchetti; F Rizzello; A Venturi; F Ugolini; M Rossi; P Brigidi; R Johansson; A Ferrieri; G Poggioli; M Campieri
Journal:  Aliment Pharmacol Ther       Date:  1999-06       Impact factor: 8.171

3.  Open label trial of oral clarithromycin in active Crohn's disease.

Authors:  K Leiper; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

4.  T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans.

Authors:  R Duchmann; E May; M Heike; P Knolle; M Neurath; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

5.  Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when.

Authors:  R Balfour Sartor
Journal:  Curr Opin Gastroenterol       Date:  2003-07       Impact factor: 3.287

6.  Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.

Authors:  P Brigidi; E Swennen; F Rizzello; M Bozzolasco; D Matteuzzi
Journal:  J Chemother       Date:  2002-06       Impact factor: 1.714

7.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

8.  Metronidazole in Crohn's disease. A double blind cross-over clinical trial.

Authors:  P Blichfeldt; J P Blomhoff; E Myhre; E Gjone
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

9.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

Authors:  R Duchmann; I Kaiser; E Hermann; W Mayet; K Ewe; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

10.  Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

Authors:  J McCarthy; L O'Mahony; L O'Callaghan; B Sheil; E E Vaughan; N Fitzsimons; J Fitzgibbon; G C O'Sullivan; B Kiely; J K Collins; F Shanahan
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  27 in total

1.  A meta-analysis of antibiotic therapy for active ulcerative colitis.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Ali Rezaie; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.199

Review 2.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 3.  Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease.

Authors:  Gert De Hertogh; Jeroen Aerssens; Karen P Geboes; Karel Geboes
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

4.  Influence of E. coli strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation.

Authors:  Ana Cristina Hernando-Harder; Rudolf von Bünau; Mahaluxmy Nadarajah; Manfred Vincenz Singer; Hermann Harder
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

Review 5.  Microbial host interactions in IBD: implications for pathogenesis and therapy.

Authors:  R Balfour Sartor; Marcus Muehlbauer
Journal:  Curr Gastroenterol Rep       Date:  2007-12

Review 6.  Role of conventional therapies in the era of biological treatment in Crohn's disease.

Authors:  Paolo Gionchetti; Carlo Calabrese; Rosy Tambasco; Ramona Brugnera; Giulia Straforini; Giuseppina Liguori; Giulia Spuri Fornarini; Donatella Riso; Massimo Campieri; Fernando Rizzello
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

7.  Probiotics increase T regulatory cells and reduce severity of experimental colitis in mice.

Authors:  Hai-Mei Zhao; Xiao-Ying Huang; Zhi-Qin Zuo; Qi-Hong Pan; Mei-Ying Ao; Feng Zhou; Hong-Ning Liu; Zhi-Yong Liu; Duan-Yong Liu
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 8.  Infectious etiopathogenesis of Crohn's disease.

Authors:  Jessica Carrière; Arlette Darfeuille-Michaud; Hang Thi Thu Nguyen
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

9.  Diverticular disease: A therapeutic overview.

Authors:  Antonio Tursi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-02-06

10.  Oral nanotherapeutics: effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis.

Authors:  Long Binh Vong; Toru Yoshitomi; Kazuya Morikawa; Shinji Saito; Hirofumi Matsui; Yukio Nagasaki
Journal:  J Gastroenterol       Date:  2013-05-29       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.